India recorded 102,562 dengue cases and 79 dengue deaths in 2025 — a 232% jump over 2024 — and projection models published in early 2026 forecast roughly 309,836 cases and up to 533 deaths in 2026. The disease is no longer a Delhi-or-Chennai monsoon nuisance. DENV-2 is the dominant serotype across central and western India, with DENV-1 and DENV-3 close behind, and the secondary heterotypic infection risk that drives severe dengue is the highest it has been in a decade.
This guide is not a generic symptom checklist. It is the operational playbook — what to actually do on day 3 of fever, which test to order on which day, why your friendly neighbourhood doctor is wrong to transfuse platelets at 60,000, why the family member who recommended a flu tablet may have come close to killing you, where the papaya leaf extract evidence actually sits, what the ICMR fluid management protocol looks like in practice, and how the new Qdenga (TAK-003) vaccine fits in. Cost ranges are India 2026. Internal links go to our companion pieces on paracetamol dosing for fever in India, hospital admission cost transparency, and the self-employed health insurance trap that matters when a dengue ICU bill arrives.
Quick Answer: Dengue is a mosquito-borne viral illness caused by four serotypes of the dengue virus, transmitted by Aedes aegypti. Hallmarks are high fever (39–40°C), severe headache, retro-orbital pain, body aches, rash, and a falling platelet count. The dangerous phase begins when the fever drops on day 3–7 — not while the fever is high. Treatment is paracetamol-only antipyresis, oral rehydration, CBC every 12–24 hours, and IV crystalloids if warning signs appear. Platelet transfusion is reserved for active bleeding or counts below 10,000 — not for the lab number itself. Avoid ibuprofen, aspirin, and combination flu tablets entirely.
What is dengue fever and why is it different from regular viral fever?
Dengue is caused by a single-stranded RNA flavivirus with four antigenically distinct serotypes — DENV-1, DENV-2, DENV-3, and DENV-4. A 2026 surveillance study from central India found DENV-2 accounted for 58.6% of isolates, followed by DENV-1 at 21.5%, DENV-3 at 17.9%, and DENV-4 at 2.0%. Recovery from one serotype gives lifelong immunity against that serotype only — and partial cross-immunity against the other three that wears off within 2–3 years. After that window, a second infection by a different serotype is the highest-risk scenario in dengue medicine, because pre-existing antibodies bind the new virus and ferry it into immune cells through a mechanism called antibody-dependent enhancement (ADE). ADE is why dengue haemorrhagic fever and dengue shock syndrome are over-represented in second infections.
The vector is Aedes aegypti (with Aedes albopictus as secondary). Unlike Anopheles (malaria) which bites at night, Aedes bites in daylight, lives indoors, breeds in clean stagnant water — the opposite of the dirty drains people assume — and lays eggs that can survive desiccation for months. Empty coolers do not stop transmission; eggs on the cooler wall hatch when you refill it three weeks later.
Dengue is also different from chikungunya, the other major Indian arbovirus carried by the same mosquito. Both produce fever, headache, and rash, but chikungunya is dominated by debilitating joint pain that often persists for months, while dengue is dominated by haemorrhagic and capillary-leak complications. CBC is what separates them — dengue causes leucopenia and progressive thrombocytopenia from day 3, chikungunya usually does not.
What are the symptoms of dengue fever — and which ones actually matter?
The textbook picture is a febrile illness with five core findings, often called “saddleback fever” because the temperature curve has a dip in the middle:
| Phase | Days | What happens | What you feel |
|---|---|---|---|
| Febrile phase | Day 1–3 | Viraemia at peak, antibody response begins | High fever 39–40°C, severe headache, retro-orbital pain, myalgia, arthralgia, flushing, rash |
| Critical phase | Day 3–7 | Fever defervesces; capillary leak begins | Fever drops — this is the danger window. Possible warning signs, shock, bleeding |
| Recovery phase | Day 7–10 | Capillary reabsorption, platelet recovery | Itchy convalescent rash, profound fatigue lasting 1–4 weeks |
The first two days look identical to influenza or a viral upper respiratory illness, which is why diagnosis based on symptoms alone is unreliable. The features that should raise dengue suspicion specifically in an Indian patient during or after monsoon:
- Retro-orbital pain — pain behind the eyes worse on eye movement
- Severe myalgia described as “break-bone” — this is the historical name for dengue
- Petechial rash — pinpoint red spots that do not blanch on pressure, often on the lower limbs and trunk by day 3–5
- Positive tourniquet test — inflate a BP cuff to mid-systolic-diastolic pressure for 5 minutes, then count petechiae in a 1-inch square below the cuff. More than 20 is suggestive
- Falling WBC count by day 3 — leucopenia precedes thrombocytopenia by 24–48 hours
What most people get wrong here: a high fever with body ache does not automatically mean dengue. But a fever with body ache that is getting worse on day 3 instead of better, with a falling platelet count and a positive NS1 test, is dengue until proven otherwise.
What are the warning signs that mean go to hospital immediately?
The WHO 2009 classification — still the operational standard — divides dengue into dengue without warning signs, dengue with warning signs, and severe dengue. The warning signs are not optional. Any single one is grounds for inpatient observation, not a “wait and watch at home” decision.
| Warning sign | What it means clinically | Required action |
|---|---|---|
| Severe abdominal pain or tenderness | Liver capsule stretching, peritoneal fluid leak | Immediate admission, USG abdomen |
| Persistent vomiting (≥3 episodes/hour) | Inability to maintain oral hydration | IV fluids, antiemetics |
| Clinical fluid accumulation (ascites, pleural effusion) | Ongoing capillary leak | Strict input-output charting, fluid recalculation |
| Mucosal bleeding (gums, nose, GI, vaginal) | Coagulopathy + thrombocytopenia | Group and crossmatch, bleeding source workup |
| Lethargy or restlessness | Cerebral hypoperfusion, early shock | Vital signs every 15 minutes |
| Liver enlargement >2 cm | Hepatic involvement | LFTs, coagulation panel |
| Rising haematocrit with rapid fall in platelets | Plasma leak in progress | Initiate IV crystalloid 5–10 ml/kg/hr |
The single highest-yield warning sign Indian families miss is severe abdominal pain at the moment the fever drops on day 4 or 5. It is interpreted as gastritis or food poisoning. It is actually plasma leak.
The CDC and WHO both note that recognising early shock and initiating intensive supportive therapy with IV fluids reduces death rate in severe dengue to under 0.5%. Late recognition produces mortality of 10–20%. The difference between those two numbers is the 6 hours after defervescence.
Which dengue test should you take on which day?
Most diagnostic confusion comes from ordering the wrong test on the wrong day and then disbelieving the result. The accuracy of each dengue test depends almost entirely on what day of illness you are on.
| Day of fever | NS1 antigen | IgM antibody | IgG antibody | RT-PCR |
|---|---|---|---|---|
| Day 1 | Positive (highest yield) | Negative | Negative | Positive |
| Day 2 | Positive (sensitivity 85–91%) | Negative | Negative | Positive |
| Day 3 | Positive (sensitivity ~80%) | Low (~43%) | Negative | Positive |
| Day 4 | Falling (~60%) | Rising (~70%) | Negative | Falling |
| Day 5 | Low (~40%) | Positive (~85%) | Detectable in primary | Negative |
| Day 6–7 | Often negative | Positive (~95%) | Positive in secondary | Negative |
| Day 8+ | Negative | 100% positive | 100% positive | Negative |
Practical reading of this table:
- Day 1–4 fever: Order NS1 antigen. Positive confirms dengue. Negative does not rule it out — repeat with NS1 + IgM on day 5.
- Day 5–7 fever: Order NS1 + IgM together. Combined accuracy hits 96–100% after day 3 onset.
- Day 7 and beyond: IgM + IgG. NS1 will be a false negative and waste money.
What most people get wrong here: a negative NS1 on day 6 is treated as “you do not have dengue.” It is treated as “the test was wrong for this stage.” Pathology labs in India routinely run NS1 on day 8 patients because doctors ordered it; the false-negative misleads the patient into stopping monitoring at exactly the critical phase.
The cost of an NS1 antigen test in India in 2026 is ₹400–₹800. The IgM/IgG dengue panel runs ₹600–₹1,200. A complete blood count (CBC) — the single most useful test in dengue — is ₹150–₹300 and should be repeated every 12–24 hours from day 3 until 48 hours after fever defervesces. CBC, not the antibody panel, is what drives the clinical decisions.
The platelet count truth — why most Indian dengue patients are over-transfused
The biggest gap between best evidence and bedside practice in India is prophylactic platelet transfusion. The patient sees a count of 40,000 and panics. The treating doctor often agrees and orders a platelet bag at ₹15,000–₹18,000 per unit. The international evidence — and ICMR, ISCCM, and the National Medical Journal of India position statements — says this is wrong.
| Platelet count | Clinical scenario | Correct action |
|---|---|---|
| > 100,000/µL | Normal | No action, continue monitoring |
| 50,000–100,000/µL | Mild dengue thrombocytopenia | Outpatient, repeat CBC q24h, oral fluids |
| 20,000–50,000/µL with no bleeding | Moderate, stable patient | Admit for monitoring. No transfusion |
| 10,000–20,000/µL with no bleeding | Severe but stable | Admit, q12h CBC. No prophylactic transfusion |
| < 10,000/µL with no bleeding | Critical | Consider transfusion case-by-case |
| Any count with active bleeding | Bleeding patient | Transfuse to achieve haemostasis |
| < 50,000 + active mucosal bleeding | Bleeding patient | Transfuse aggressively |
The rule the expert group at the ISCCM 2023 position statement is most explicit about: prophylactic platelet transfusion in dengue produces longer hospital stays, higher transfusion-related lung injury, fluid overload, and no measurable benefit on bleeding outcomes. Multiple Indian RCTs have shown this independently.
What this means for a patient: if your count is 28,000 and you are conscious, urinating, not bleeding, not in shock, and your haematocrit is stable, the correct treatment is observation, oral hydration, and a repeat CBC in 12 hours — not a ₹17,000 transfusion. If the doctor insists on prophylactic transfusion without bleeding, ask whether the decision follows ISCCM 2023 or ICMR guidance, and request that the rationale be documented in the case sheet. This is not patient hostility — it is informed consent on a high-risk intervention.
What most people get wrong here: the platelet number is treated as the disease. The actual disease in severe dengue is plasma leak from increased capillary permeability — and that is detected by rising haematocrit, narrowing pulse pressure, and reduced urine output, not by the platelet graph.
ICMR / NCDC fluid management — what the protocol actually looks like
Most dengue deaths are preventable, and the lever is fluid management. The framework comes from the NVBDCP / NCDC Guidelines for Clinical Management of DF/DHF/DSS (downloadable from the National Centre for Vector Borne Diseases Control) and the ISCCM 2023 position statement.
Group A — dengue without warning signs, stable:
- Manage at home with oral rehydration: ORS, coconut water, kanji, rice water, soups
- Paracetamol 500–650 mg every 6 hours, maximum 4 grams per day for adults; 10–15 mg/kg per dose for children
- Daily CBC from day 3
- Strict avoidance of NSAIDs, aspirin, steroids unless specifically indicated
- Output target: pale urine every 4–6 hours
Group B — dengue with warning signs, or comorbid conditions:
- Admit. IV crystalloid (0.9% normal saline or Ringer’s lactate) at 5–10 ml/kg/hr for 1 hour
- Reassess at 1 hour. If haematocrit and vitals improving, taper to 3–5 ml/kg/hr for 2–4 hours, then 2–3 ml/kg/hr
- If no improvement, escalate to 10 ml/kg/hr crystalloid bolus
- Hourly vitals, 6-hourly CBC, strict input-output charting
- Watch for the 24–48 hour critical phase post-defervescence
Group C — severe dengue (DHF, DSS):
- ICU admission
- 10–20 ml/kg crystalloid bolus over 15 minutes for compensated shock, repeat if needed
- Switch to colloid (gelatin or 6% HES — use cautiously) for refractory shock
- Blood transfusion if HCT falls despite fluid resuscitation (suggests occult bleeding)
- Vasopressor support if hypotension persists after adequate fluid loading
Choice of crystalloid: normal saline is the default. If the patient has hyperchloraemic acidosis, hypernatraemia, or develops hyperchloraemia during resuscitation, switch to Ringer’s lactate. This nuance is missed in most Indian non-tertiary centres and contributes to renal complications.
What medicines to take — and the ones that can kill you
The pharmacology of dengue is unusual. Almost every common Indian over-the-counter “flu remedy” is contraindicated.
| Drug | Status in dengue | Why |
|---|---|---|
| Paracetamol (acetaminophen) | Safe — first line | No platelet effect, no GI bleeding risk |
| Ibuprofen | Avoid | Reversible platelet dysfunction, gastric erosion, increased bleeding risk |
| Aspirin | Avoid — absolute | Irreversible antiplatelet effect for 7–10 days, severe bleeding risk |
| Naproxen, diclofenac | Avoid | Same NSAID mechanism as ibuprofen |
| Combination flu tablets (e.g. with ibuprofen or aspirin) | Avoid | Hidden NSAID content |
| Mefenamic acid (Meftal) | Avoid | NSAID — same bleeding risk |
| Steroids (dexamethasone, prednisolone) | Avoid routine use | Cochrane reviews show no benefit and possible harm in severe dengue |
| Antibiotics | Not indicated unless secondary bacterial infection | Dengue is viral; routine antibiotic prophylaxis is inappropriate |
| Carica papaya leaf extract (Caripill, Carispan) | Reasonable adjunct | RCT evidence of modest platelet recovery benefit |
Paracetamol dosing is genuinely safe at 500–650 mg every 6 hours up to 4 grams/day for adults. Read our full Dolo 650 / paracetamol India dosing guide for hepatic safety thresholds. The Indian habit of combining paracetamol with ibuprofen for “stubborn fever” is exactly what causes preventable upper GI bleeding in dengue patients.
The papaya leaf extract question:
The Carica papaya leaf extract studies are sometimes dismissed as folk medicine and sometimes oversold as miracle cure. Both extremes are wrong.
- A multi-centric double-blind placebo-controlled RCT of 300 Indian patients (registration CTRI/2015/05/005806) showed statistically significant increase in platelet count versus placebo
- A pilot study in severe thrombocytopenia (≤30,000/µL) showed median time to platelet recovery to ≥50,000 was 2 days versus 3 days in placebo, and fewer patients in the treatment arm required transfusions
- Multiple Indian studies in paediatric subjects show enhanced platelet-activating factor receptor activity around 13-fold and ALOX-12 activity 15-fold — a biologically plausible mechanism
What the evidence does not say: that papaya leaf extract replaces fluids, monitoring, or transfusion in severe dengue. It is a reasonable low-risk adjunct in mild to moderate cases. Caripill (Microlabs) and Carispan are the two standardised formulations sold in Indian pharmacies. Crushed papaya leaf juice from a home remedy is not standardised and not safe to assume equivalent.
The dengue critical phase — the 24–48 hour window that kills people
The single most important fact in dengue management is this: the worst phase of dengue begins when the fever drops, not while the fever is high. Indian families and even some clinicians relax at defervescence on day 4 or 5. That is the exact moment to escalate vigilance.
What happens biologically: viral load falls, the immune response peaks, cytokine release induces increased capillary permeability, plasma leaks out of vessels into pleural and peritoneal spaces, the effective intravascular volume drops, and the patient slides toward hypovolaemic shock — sometimes silently. The patient often looks deceptively well in early shock — alert, talking, denying symptoms. This is called compensated shock, and within hours it decompensates.
| Sign | Compensated shock | Decompensated shock |
|---|---|---|
| Mental status | Alert, anxious | Drowsy, confused, agitated |
| Capillary refill | 2–3 seconds | > 3 seconds |
| Peripheral pulses | Weak | Absent |
| Pulse pressure | Narrow (<20 mmHg) | Unrecordable |
| Systolic BP | Normal or slightly low | Profoundly low |
| Urine output | Reduced | Absent |
A patient with pulse pressure of 18 mmHg, cool peripheries, and capillary refill of 3 seconds is in shock — even if the BP is 100/82 and the patient is talking. That is the most-missed clinical scenario in Indian non-ICU wards.
The CDC notes that with timely intervention severe dengue mortality is under 0.5%. Without it, mortality is 10–20%. The difference is whether someone counted the pulse pressure and started a 10 ml/kg crystalloid bolus within the first 30 minutes of recognising the warning signs.
Dengue in pregnancy — what the FOGSI guidance actually says
Dengue in pregnancy carries elevated maternal and foetal risk and demands a separate management approach. The Federation of Obstetric and Gynaecological Societies of India (FOGSI) and several Indian academic studies have characterised this risk profile.
Maternal risks:
- Higher risk of severe dengue, especially in second and third trimester
- Postpartum haemorrhage at delivery while thrombocytopenia is active
- Preterm labour
- Hypertensive disorders confounded by capillary leak
- Increased risk of caesarean section
Foetal and neonatal risks:
- Vertical transmission in roughly 1–6% of cases, with risk rising sharply if infection occurs within 10 days of delivery
- Preterm birth and low birth weight
- Neonates born to actively infected mothers should be monitored for 14 days for symptom onset
- Most affected neonates become symptomatic between day 4 and day 11 after birth
Management essentials in pregnancy:
- Strict avoidance of NSAIDs (including for postpartum analgesia), aspirin, and ergometrine (uterotonic) due to bleeding and shock risk
- Serial CBC every 12 hours from diagnosis
- Inpatient observation for any warning sign even in the first trimester
- Notify the paediatric team and arrange neonatal monitoring if delivery occurs during active maternal infection
- Counsel on extended breastfeeding safety — current consensus is that breastfeeding is not contraindicated even with active maternal dengue
For the broader picture on thyroid, hypertension, and infection management during pregnancy, see our thyroid in pregnancy India guide and pregnancy cost breakdown in Indian hospitals.
How much does dengue treatment actually cost in India?
Treatment cost is wildly variable depending on whether the case is outpatient, admitted, or in ICU. The numbers below are 2026 ranges from Indian referral hospital data, ManipalCigna and PolicyX healthcare cost reports, and a published cost-of-illness study from a tertiary referral hospital.
| Scenario | Cost range (₹) | What’s included |
|---|---|---|
| Outpatient dengue, no admission | 3,000–8,000 | NS1 + CBC monitoring, doctor consults, paracetamol, ORS |
| Day-care infusion for borderline case | 8,000–18,000 | IV fluids, repeat CBC, observation, no overnight stay |
| Inpatient — dengue with warning signs | 25,000–60,000 | 3–5 day ward stay, daily CBC, IV fluids, doctor visits |
| Severe dengue without ICU | 50,000–1,20,000 | 5–7 day stay, intensive monitoring, possible 1 platelet bag |
| Severe dengue with ICU + DSS | 1,50,000–4,50,000 | ICU stay, multiple transfusions, colloids, vasopressors |
| Pediatric severe dengue (published median direct cost) | ~70,000–80,000 (~US$933) | Published Indian referral hospital data |
| Adult severe dengue (published median direct cost) | ~55,000–65,000 (~US$720) | Published Indian referral hospital data |
| Single-donor platelet (SDP) bag | 15,000–18,000 | Per unit; severe cases may need 2–4 |
| Random-donor platelet bag | 400–700 per unit | Less effective, used in pools of 4–6 |
Note: ICU costs in private Indian hospitals run around $901 per episode in published research — that is roughly ₹75,000 in 2026 rupees, just for the ICU bed, before transfusions and consultant fees.
The implications for an uninsured family in a tier-1 city are stark. A severe dengue ICU admission for an adult can produce an out-of-pocket bill of ₹2.5–4 lakh — easily 15–25% of annual household income for a middle-income family. The cost analysis in our Max Hospital real bill breakdown piece walks through specific line items for infectious disease admissions; the same patterns apply to private dengue admissions in Apollo, Manipal, Fortis, and Medanta.
For a self-employed or freelancer family, this is exactly the scenario the self-employed health insurance guide was written for — a single ICU admission collapses the household budget if there is no cover or the cover is inadequate.
The Qdenga (TAK-003) vaccine — what to know in 2026
Dengue vaccine development has been long and bumpy. The first vaccine, Dengvaxia (Sanofi), proved safe and effective only in people with prior dengue exposure — and increased severe dengue risk in dengue-naive individuals due to ADE. It was discontinued in Brazil in February 2025 and is not in routine Indian use.
The second-generation vaccine — Qdenga (TAK-003), from Takeda — was approved by India’s DCGI in 2024 for ages 4 to 60 years, subject to a post-marketing safety and effectiveness study within six months of introduction. It is a tetravalent live attenuated vaccine, two doses given subcutaneously three months apart, and unlike Dengvaxia does not require prior dengue exposure to be safely administered. Verify the approval status and prescribing information on the Central Drugs Standard Control Organisation (CDSCO) portal before vaccination.
The 7-year TIDES (Tetravalent Immunization against Dengue Efficacy Study) Phase 3 data published by Takeda in late 2025 showed:
- Sustained protection against all four serotypes through 7 years
- Strong efficacy against hospitalised dengue
- Favourable benefit-risk profile in seronegative and seropositive populations
- No evidence of vaccine-induced ADE at long-term follow-up
The WHO recommends Qdenga for children aged 6 to 16 in high-burden regions. Real-world rollout in India in 2026 is happening in private clinics at a price of roughly ₹6,000–₹9,000 per dose. The vaccine is not yet on the Universal Immunization Programme schedule, and the government’s National Centre for Vector Borne Diseases Control (NCVBDC) is the body monitoring post-marketing data.
Who should consider Qdenga in India:
- Residents of high-burden states — Tamil Nadu, Karnataka, Maharashtra, West Bengal, Delhi-NCR, Andhra Pradesh, Kerala
- Adults with documented prior dengue infection (highest individual benefit due to ADE protection)
- Healthcare workers in endemic zones
- Frequent monsoon-season travellers to endemic regions
- Children in repeated-outbreak neighbourhoods, after paediatrician counselling
Who should defer: pregnant women, immunocompromised individuals, those on active high-dose steroid therapy, and those with prior severe allergic reaction to any vaccine component.
Prevention — what actually works against Aedes aegypti in India
The fogging trucks that municipalities run during outbreaks are largely cosmetic. They kill some adult mosquitoes but do nothing to eliminate breeding sites, which are mostly inside private homes and on private terraces. Sustained prevention is source reduction at the household level. A Delhi-based intervention study published in PLOS One showed that community-led source reduction during transmission months produced significant reductions in dengue breeding indices.
The six interventions with real impact:
- Empty and scrub coolers weekly. Draining is not enough — Aedes eggs survive desiccation for months and hatch on next refill. Scrub the walls with a brush and detergent.
- Cover overhead tanks and underground sumps with mosquito-proof mesh. A single uncovered tank is a multi-hundred-larvae factory.
- Drain or remove standing water from flower pot saucers, fridge drip trays, AC drain pans, terrace rubble, discarded tyres, coconut shells, broken bottles.
- Use repellents with 20–30% DEET, picaridin, or oil of lemon eucalyptus on exposed skin during peak biting hours — early morning 6 am–8 am and late afternoon 4 pm–6 pm. Avoid citronella-only formulations, which give poor protection duration.
- Mosquito mesh on windows and bed nets in children’s rooms. Aedes lives indoors during the day.
- Wear long sleeves and trousers during peak biting hours, especially in monsoon and post-monsoon months.
Always check the latest WHO and CDC dengue advisories — the WHO dengue and severe dengue fact sheet and the CDC dengue clinical guidance are authoritative reference points for clinicians and patients. The CDC’s classification system is the basis for the warning-sign framework used in most Indian tertiary hospitals.
What to do — a concrete day-by-day protocol for suspected dengue in India
Putting it together, here is what to actually do if you wake up on day 1 with high fever, severe body ache, and headache during or after monsoon in an endemic Indian region.
| Day | Action | Why |
|---|---|---|
| Day 1 | Doctor visit, NS1 antigen + CBC. Paracetamol only. ORS, coconut water, kanji. Document baseline. | NS1 has highest yield in first 3 days. CBC establishes baseline platelet count. |
| Day 2 | Repeat CBC if any worsening. Continue paracetamol. Track temperature and urine output. | Leucopenia precedes thrombocytopenia by 24–48 hours. |
| Day 3 | CBC. Tourniquet test if rash present. Watch fever curve. Avoid every NSAID and combination tablet. | Day 3 is when platelets begin falling. Most diagnoses confirmed here. |
| Day 4 | The critical day. If fever drops, increase vigilance — do not relax. Hospital evaluation if any warning sign. | Critical phase begins at defervescence. Plasma leak risk highest in next 48 hours. |
| Day 5 | Continued CBC every 12–24 hours. If admitted, IV fluids per protocol. Watch pulse pressure, capillary refill. | Compensated shock can hide behind alert mental status. |
| Day 6 | If stable, continue monitoring. If platelet count < 20,000 with bleeding, hospital. | Bleeding plus thrombocytopenia is the transfusion trigger, not the count alone. |
| Day 7 | Most patients recovering. CBC daily until platelet count rising. Convalescent rash may appear. | Capillary leak reverses. Fluid overload is now the risk, not dehydration. |
| Day 8–10 | Recovery, profound fatigue expected. Resume normal activity gradually. | Fatigue can persist 1–4 weeks. Not a sign of complication. |
Based on patient reports across Indian tertiary centres, the single most predictive feature of a bad outcome is discharge on day 4 because the fever resolved. The single most protective feature is inpatient observation through the entire critical phase regardless of how well the patient looks.
Sources and references
Authoritative primary sources used in this guide:
- WHO — Dengue and severe dengue fact sheet
- CDC — Clinical features of dengue and warning signs
- CDC — Guidelines for classifying dengue
- CDC — Clinical testing guidance for dengue (NS1, IgM, IgG, RT-PCR)
- India — National Centre for Vector Borne Diseases Control (NCVBDC), MoHFW
- NVBDCP — Guidelines for Clinical Management of DF/DHF/DSS
- ISCCM 2023 Position Statement — Management of Severe Dengue in the Intensive Care Unit
- CDSCO — Central Drugs Standard Control Organisation (Qdenga approval status)
- Takeda — 7-year TIDES Phase 3 data on Qdenga (TAK-003), November 2025
- FOGSI — Dengue in Pregnancy Management Protocols
- Carica papaya leaf extract — multi-centric Indian RCT, CTRI/2015/05/005806
- PLOS ONE — Papaya leaf extract in severe dengue thrombocytopenia, pilot RCT
- PLOS ONE — Aedes aegypti breeding control intervention, Delhi
- Frontiers in Tropical Diseases — Circulating dengue serotypes in central India, 2026
- Dengue dynamics in India — ARIMA model 2025 projections
Medical disclaimer
This article is for educational purposes only and does not constitute medical advice. Dengue can rapidly become life-threatening, especially during the critical phase between day 3 and day 7 of illness. Any high fever during or after monsoon, especially with severe headache, retro-orbital pain, body aches, or rash, should be evaluated by a qualified medical practitioner. Do not self-medicate. Do not delay seeking emergency care if you or someone you are caring for develops any warning sign — severe abdominal pain, persistent vomiting, mucosal bleeding, drowsiness, restlessness, cold clammy skin, or reduced urine output. Always verify drug dosing, vaccine eligibility, and clinical protocols against the current guidance of the National Centre for Vector Borne Diseases Control (NCVBDC), ICMR, and your treating physician.